Municipality Finance issues EUR 50 million notes under its MTN programme
Municipality Finance Plc
Stock exchange release
1 November 2023 at 10:00 am (EET)
Municipality Finance issues EUR 50 million notes under its MTN programme
Municipality Finance Plc issues EUR 50 million notes on 2 November 2023. The maturity date of the notes is 2 November 2043. MuniFin has a right, but no obligation, to redeem the notes early on 2 November 2029. The notes bear interest at a fixed rate of 4.287% per annum.
The notes are issued under MuniFin’s EUR 45 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and the final terms of the notes are available in English on the company's website at www.munifin.fi/investor-relations.
MuniFin has applied for the notes to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 2 November 2023.
DekaBank Deutsche Girozentrale acts as the dealer for the issue of the notes.
MUNICIPALITY FINANCE PLC
Executive Vice President, Capital Markets and Sustainability
tel. +358 50 444 3638
MuniFin (Municipality Finance Plc) is one of Finland’s largest credit institutions. The owners of the company include Finnish municipalities, the public sector pension fund Keva and the Republic of Finland. MuniFin Group also includes the subsidiary company, Financial Advisory Services Inspira Ltd. The Group’s balance sheet totals approximately EUR 48 billion.
MuniFin builds a better and more sustainable future with its customers. Our customers include municipalities, joint municipal authorities, wellbeing services counties, joint county authorities, corporate entities under the control of the above-mentioned organisations, and affordable social housing. Lending is used for environmentally and socially responsible investment targets such as public transportation, sustainable buildings, hospitals and healthcare centres, schools and day care centres, and homes for people with special needs.
MuniFin’s customers are domestic but the company operates in a completely global business environment. The company is an active Finnish bond issuer in international capital markets and the first Finnish green and social bond issuer. The funding is exclusively guaranteed by the Municipal Guarantee Board.
Read more: www.munifin.fi
The information contained herein is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into any such country or jurisdiction or otherwise in such circumstances in which the release, publication or distribution would be unlawful. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any securities or other financial instruments in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.
This communication does not constitute an offer of securities for sale in the United States. The notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of any state of the United States and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)27.2.2024 21:52:04 CET | Press release
Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955). The study, A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections is being conducted under a contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Approximately 80 sites
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons27.2.2024 21:42:24 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameAnthony Pagano2.Reason for the notificationa)Position/statusExecutive Vice President & Chief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction pla
Capital Increase in Genmab as a Result of Employee Warrant Exercise27.2.2024 21:40:01 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00, 19,631 shares at DKK 1,032.00, 2,473 shares at DKK 1,050.00, 1,422 shares at DKK 1,161.00, 40 shares at DKK 1,334.50, 1,036 shares at DKK 1,362.50, 6,660 shares at DKK 1,402.00, 129 shares at DKK 1,408.00, and 9,713 shares at DKK 1,615.00. Proceeds to the company are approximately DKK 58.7 million. The increase corresponds to approximately 0.07% of the company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as
Nova Klúbburinn hf. birtir uppgjör fjórða ársfjórðungs og ársins 202327.2.2024 18:43:15 CET | Press release
Sterkur vöxtur þjónustutekna skilar sér í hækkun EBITDA, auknum hagnaði og betra sjóðstreymi Helstu niðurstöður á fjórða ársfjórðungi: Heildartekjur voru 3.327 m.kr. á fjórða ársfjórðungi 2023 samanborið við 3.354 m.kr. á Á samanburðarári tekjufærði félagið einskiptislið að fjárhæð 39 m.kr. vegna sölu eigna, leiðrétt fyrir því er 0,05% tekjuvöxtur á milli áraÞjónustutekjur námu samtals 2.424 m.kr. og vaxa um 3,4% á milli ára EBITDA nam 961 m.kr. samanborið við 978 m.kr. á sama tímabili á fyrra ári, EBITDA hlutfallið var 28,9% á fjórðungnum samanborið við 29,2% á fyrra ári Hagnaður fjórða ársfjórðungs var 182 m.kr. og hækkar um 3,9%Handbært fé frá rekstri á fjórðungnum er 1.010 m.kr. samanborið við neikvætt 110 m.kr. á sama tímabili á fyrra ári Helstu niðurstöður ársins 2023: Heildartekjur voru 12.993 m.kr. á árinu 2023 samanborið við 12.641 m.kr. á árinu 2022 og vaxa um 2,8% milli áraÞjónustutekjur námu samtals 9.734 m.kr. og vaxa um 6,8% á milli ára EBITDA nam 3.979 m.kr. og hækkar um
Open Society Foundations’ Soros Economic Development Fund Commits $25 Million to Allied Climate Partners’ Climate Finance Partnership27.2.2024 18:41:57 CET | Press release
New York, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The Soros Economic Development Fund (SEDF), the impact investment arm of the Open Society Foundations, is committing $25 million to Allied Climate Partners (ACP)—a new and innovative public-private partnership focused on increasing the number of bankable climate projects in emerging markets and developing economies around the world. ACP aims to address a critical financing gap at the early, risk-oriented stages of the development process. Without this support, many projects and businesses struggle to attract the necessary capital to achieve their climate-related goals. While early-stage project development represents the smallest portion of the overall funding needed for a project (approximately 5 percent), relatively few early-stage projects get financed due to risk. Even though 5 percent of the capital can unlock 95 percent, this early-stage capital is the hardest to raise for critical activities like technical and environmental assessments